Leaked details of free trade negotiations between New Zealand and the United States show the two countries are in stark opposition on a number of key areas.
Since announcing the Comprehensive Economic and Trade Agreement (CETA) two weeks ago Harper’s Conservatives have repeatedly labelled those questioning the deal as “anti-trade”. But this Canada-European Union accord is one part trade and four parts ‘corporate bill of rights’.
The federal government won’t release internal documents that may predict potential higher drug costs for Canadians under new patent rules agreed to in the free-trade deal with Europe, Trade Minister Ed Fast says.
The far reaching provisions of the Comprehensive Economic and Trade Agreement between Canada and the European Union will have considerable impact on Canada’s IP regime.
18-Oct-2013 Radio Canada
Ottawa, comme d’autres provinces canadiens, exigera des compensations financières pour certains de ses secteurs économiques qui risquent de souffrir du nouvel accord de libre-échange entre le Canada et l’Union européenne.
2-Oct-2013 Dissent Magazine
The struggle for access to medicine presents a legal and ethical minefield for rich and poor countries alike—one that is being fought out as humanitarians challenge corporations over intellectual property rights.
US puts unwarranted pressure on India for taking legal steps to increase access to affordable medicines
India is facing an onslaught of political pressure from the U.S. government and pharmaceutical industry in retaliation for the country’s entirely legal actions to limit abusive patenting practices and increase access to affordable generic medicines
18-Sep-2013 ACT UP Paris
Communiqué de presse interassociatif (Act Up-Paris, HAI, Oxfam, Action against AIDS)
16-Sep-2013 Bangkok Post
Thai trade representative Olarn Chaiprawat has given civil society groups a confirmation that "TRIPS-plus" and drug issues will not be included in the Thai-EU FTA negotiations.
Once again, our government is negotiating a trade deal in secret — and once again, the chorus of “free market” fundamentalists is assuring us that what’s good for lining corporate pockets must be good for us all.
Malaysia should exclude medical and tobacco businesses in the ongoing free trade talks under the Trans-Pacific Partnership Agreement (TPPA).
Alianza LAC - Global por el Acceso a Medicamentos: el TPP amenaza el acceso a medicamentos asequibles
"Rechazamos y denunciamos la falta de transparencia en la que se desarrollan las negociaciones, constituyendo un proceso nada democrático, sin participación de los parlamentos nacionales ni de la sociedad civil. El futuro de alrededor de 700 millones de personas no se puede negociar en secreto."
Canada is pushing back against a campaign by activists trying to block what they say are onerous intellectual property rules that would raise the price of pharmaceuticals in poor countries.
3-Jul-2013 Programa de las Américas
¿Qué significa realmente el TPP (Asociación del Transpacífico) para América Latina?
As host to both the AIDS conference and TPP trade talks this month, Malaysia reportedly vows to reject a TPP trade agreement that harms access to medicines; other countries should follow suit, and Malaysia should be held to its pledge
30-Jun-2013 South Centre
Bilateral investment treaties (BITs) may be a threat to access to medicines as shown by a recent legal suit by a drug multinational against Canada for invalidating a patent, writes Carlos Correa
Are the PBS and Pharmac under threat from the TPP? Certainly, the respective governments of both Australia and New Zealand think not. So why then the paranoia? Quite simply, we need the US more than they need us. In order to secure the TPP (and with it, for example, access to the lucrative US dairy market), both Australia and New Zealand will likely need to yield in several key areas.
Live from the TPP: IP chapter shows no sign of resolution, end of negotiation in 2013 highly unlikely
There is a strong sense in the halls of the current TPP negotiation that the end is not in sight. And one of the primary reasons s a lack of consensus on intellectual property and pharmaceuticals issues, reports Infojustice from Lima.
Although access to medicines activists have been wise to focus our attention intently on convincing low- and middle-income countries to adopt and use all possible TRIPS-compliant flexibilities and to oppose the TRIPS-plus IP chapters in free trade agreements, we have neglected to interrogate another chapter in free trade agreements and bilateral investment treaties that perhaps pose an even greater threat to our collective access to medicines – investment chapters.
The much-hyped bilateral trade and investment agreement (BTIA) between India and the European Union (EU) would not impact the Indian generic drugs industry or lead to a change in the country’s patent law, João Cravinho, EU ambassador to India, said on Friday.